496 related articles for article (PubMed ID: 28360208)
21. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Skougaard K; Nielsen D; Jensen BV; Hendel HW
J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497
[TBL] [Abstract][Full Text] [Related]
22. [Stable disease or complete response? : A critical evaluation of the radiologic response to immune checkpoint blockade in advanced melanoma].
Tietze JK; Heppt M; Angelova D; Ruzicka T; Berger F; Berking C
Hautarzt; 2017 Aug; 68(8):632-638. PubMed ID: 28382381
[TBL] [Abstract][Full Text] [Related]
23. TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.
Ho KC; Fang YD; Chung HW; Liu YC; Chang JW; Hou MM; Yang CT; Cheng NM; Su TP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2155-2165. PubMed ID: 27260520
[TBL] [Abstract][Full Text] [Related]
24.
Dercle L; Seban RD; Lazarovici J; Schwartz LH; Houot R; Ammari S; Danu A; Edeline V; Marabelle A; Ribrag V; Michot JM
J Nucl Med; 2018 Jan; 59(1):15-24. PubMed ID: 28596157
[TBL] [Abstract][Full Text] [Related]
25. A pilot study on EORTC or PERCIST for the prediction of progression-free survival with nivolumab therapy in advanced or metastatic gastric cancers: A STROBE-compliant article.
Nakajo M; Kitajima K; Toriihara A; Arigami T; Daisaki H; Nakamura A; Ohtsuka T; Miwa H; Yoshiura T
Medicine (Baltimore); 2021 Apr; 100(15):e25494. PubMed ID: 33847661
[TBL] [Abstract][Full Text] [Related]
26. Predictive value and accuracy of [
Ayati N; Jamshidi-Araghi Z; Hoellwerth M; Schweighofer-Zwink G; Hitzl W; Koelblinger P; Pirich C; Beheshti M
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2715-2726. PubMed ID: 37140669
[TBL] [Abstract][Full Text] [Related]
27. The value of
Ayati N; Sadeghi R; Kiamanesh Z; Lee ST; Zakavi SR; Scott AM
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):428-448. PubMed ID: 32728798
[TBL] [Abstract][Full Text] [Related]
28. Clinical Value of
Hynninen J; Laasik M; Vallius T; Kemppainen J; Grönroos S; Virtanen J; Casado J; Hautaniemi S; Grenman S; Seppänen M; Auranen A
Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):507-514. PubMed ID: 29753662
[TBL] [Abstract][Full Text] [Related]
29. 18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab.
Sachpekidis C; Kopp-Schneider A; Hakim-Meibodi L; Dimitrakopoulou-Strauss A; Hassel JC
Melanoma Res; 2019 Apr; 29(2):178-186. PubMed ID: 30653029
[TBL] [Abstract][Full Text] [Related]
30. The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III-IV BRAF -Mutated Melanoma Patients Treated With Targeted Therapy-What Can Be Learned From Progression?
van der Hiel B; Aalbersberg EA; van den Eertwegh AJM; de Wit-van der Veen LJ; Stokkel MPM; Lopez-Yurda M; Boellaard R; Kapiteijn EW; Hospers GAP; Aarts MJB; de Vos FYFL; Boers-Sonderen MJ; van der Veldt AAM; de Groot JWB; Haanen JBAG
Clin Nucl Med; 2024 Feb; 49(2):138-145. PubMed ID: 38113329
[TBL] [Abstract][Full Text] [Related]
31. Longitudinal studies of the
Sachpekidis C; Anwar H; Winkler JK; Kopp-Schneider A; Larribere L; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
Cancer Immunol Immunother; 2018 Aug; 67(8):1261-1270. PubMed ID: 29872898
[TBL] [Abstract][Full Text] [Related]
32.
Nienhuis PH; Antunes IF; Glaudemans AWJM; Jalving M; Leung D; Noordzij W; Slart RHJA; de Vries EFJ; Hospers GAP
J Nucl Med; 2022 Jun; 63(6):899-905. PubMed ID: 34503964
[TBL] [Abstract][Full Text] [Related]
33. FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST.
Depardon E; Kanoun S; Humbert O; Bertaut A; Riedinger JM; Tal I; Vrigneaud JM; Lasserre M; Toubeau M; Berriolo-Riedinger A; Dygai-Cochet I; Fumoleau P; Brunotte F; Cochet A
PLoS One; 2018; 13(7):e0199529. PubMed ID: 30011328
[TBL] [Abstract][Full Text] [Related]
34. The Role of PET/CT in the Era of Immune Checkpoint Inhibitors: State of Art.
Castello A; Lopci E
Curr Radiopharm; 2020; 13(1):24-31. PubMed ID: 31749440
[TBL] [Abstract][Full Text] [Related]
35. Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer.
Riedl CC; Pinker K; Ulaner GA; Ong LT; Baltzer P; Jochelson MS; McArthur HL; Gönen M; Dickler M; Weber WA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1428-1437. PubMed ID: 28462446
[TBL] [Abstract][Full Text] [Related]
36. FDG PET scans as evaluation of clinical response to dendritic cell vaccination in patients with malignant melanoma.
Engell-Noerregaard L; Hendel HW; Johannesen HH; Alslev L; Svane IM
Cancer Immunol Immunother; 2013 Jan; 62(1):17-25. PubMed ID: 22722450
[TBL] [Abstract][Full Text] [Related]
37. Treatment response evaluation with
Sachpekidis C; Hillengass J; Goldschmidt H; Wagner B; Haberkorn U; Kopka K; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):50-62. PubMed ID: 27573638
[TBL] [Abstract][Full Text] [Related]
38. Textural features in FDG-PET/CT can predict outcome in melanoma patients to treatment with Vemurafenib and Ipililumab.
Dittrich D; Pyka T; Scheidhauer K; Lütje S; Essler M; Bundschuh RA
Nuklearmedizin; 2020 Jun; 59(3):228-234. PubMed ID: 32259852
[TBL] [Abstract][Full Text] [Related]
39. Assessing immune organs on
Prigent K; Lasnon C; Ezine E; Janson M; Coudrais N; Joly E; Césaire L; Stefan A; Depontville M; Aide N
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2573-2585. PubMed ID: 33432374
[TBL] [Abstract][Full Text] [Related]
40. Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0.
Odawara S; Kitajima K; Katsuura T; Kurahashi Y; Shinohara H; Yamakado K
Eur J Radiol; 2018 Apr; 101():65-71. PubMed ID: 29571803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
